Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT7 | O95251 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | CPS1 | P31327 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23512595 | 1.00 | KAT7 (0.41) | KAT7USP30SCN9APARP1SETD7 | |
| SCHEMBL29826014 | 1.00 | KAT7 (0.41) | KAT7USP30SCN9APARP1SETD7 | |
| SCHEMBL23512565 | 1.00 | KAT7 (0.41) | KAT7USP30SCN9APARP1SETD7 | |
| SCHEMBL29825651 | 0.93 | KAT7 (0.40) | KAT7USP30SCN9APARP1SETD7 | |
| SCHEMBL23512843 | 0.93 | KAT7 (0.40) | KAT7USP30SCN9APARP1SETD7 | |
| SCHEMBL29826018 | 0.93 | KAT7 (0.40) | KAT7USP30SCN9APARP1SETD7 | |
| SCHEMBL23512649 | 0.93 | KAT7 (0.40) | KAT7USP30SCN9APARP1SETD7 | |
| SCHEMBL24558215 | 0.91 | USP30 (0.41) | KAT7USP30SCN9APARP1SETD7 | |
| SCHEMBL24558430 | 0.89 | USP30 (0.40) | KAT7USP30SCN9APARP1SETD7 | |
| SCHEMBL24558458 | 0.86 | KAT7 (0.44) | KAT7USP30PARP1SETD7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| CN-113508118-B | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-3935060-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2023-11-15 | — | — | EP | disclosed |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| US-11731984-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3886991-B1 | KRAS G12C INHIBITORS | LILLY CO ELI (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | MCL1, TP53, CCNA2 | KAT7 1949/4885USP30 4265/4885SCN9A 4268/4885 |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | KRAS, NRAS, GLS2 | KAT7 2179/4885USP30 3416/4885SCN9A 2190/4885 |
| US-11731984-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | KAT7 2978/4885USP30 2637/4885SCN9A 1639/4885 |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | MCL1, TP53, CCNA2 | KAT7 1949/4885USP30 4265/4885SCN9A 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.